A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)

BACKGROUND: Neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACR) are the standard treatments for esophageal squamous cell carcinoma (ESCC). However, the 5-year overall survival (OS) rate is still far from satisfactory. In recent years, immune checkpoint inhibitors (ICIs) have show...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yan, Liu, Xian-Ben, Sun, Hai-Bo, Xu, Jinliang, Shen, Sining, Ba, Yu-Feng, Yan, Ming, Qin, Zimin, Liu, Bao-Xing, Wang, Zong-Fei, Liu, Shi-Lei, Zhang, Rui-Xiang, Chen, Pei-Nan, Liang, Guang-Hui, Yuan, Dongfeng, Li, Zhen-Xuan, Liu, Qi, Wang, Hao-Ran, Li, Hao-Miao, Lv, Hongwei, Ma, Xiaochao, Zhu, Jianping, Yu, Yong-Kui, Xing, Wen-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859818/
https://www.ncbi.nlm.nih.gov/pubmed/33553366
http://dx.doi.org/10.21037/atm-20-5404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859818/
https://www.ncbi.nlm.nih.gov/pubmed/33553366
http://dx.doi.org/10.21037/atm-20-5404

Ejemplares similares